HK Stock Market Move | HENLIUS (02696) surges over 8% again, B7-H3 sialidase fusion protein HLX316 clinical research application approved.

HENLIUS (02696) rose by more than 8%, as of the time of writing, it has increased by 5.08%, reaching HK$69.3, with a turnover of HK$33.731 million. On the news front, on March 9th, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that the Class 1 new drug injection HLX316 developed by HENLIUS has been approved for clinical trials for the treatment of advanced/metastatic solid tumors. Public information indicates that this is a B7H3-sialylase fusion protein. As of the date of this announcement, there is still no sialylase Fc fusion protein targeting B7-H3 approved for marketing worldwide. Furthermore, the 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark from March 25th to 28th. ELCC is a top academic event in the field of lung cancer in Europe and even globally. At this congress, several studies on HENLIUS' innovative anti-PD-1 monoclonal antibody HANSRU (sulterituzumab) developed independently by HENLIUS have been selected, covering the treatment of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) fields.